REFERENCES
1. Aldana Blanco B, Langenbeck’s CLW. Liquid biopsy for the detection and management of surgically resectable tumors. Arch Surg 2019;404:517-25.
2. Hyun KA, Gwak H, Lee J, Kwak B, Jung H. Salivary exosome and cell-free DNA for cancer detection. Micromachines 2018;9:340.
3. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision. Med Cancer Res 2019;9:2798-804.
4. Geeurickx E, Hendrix A. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Mol Aspects Med 2020;72:100828.
6. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016;387:1094-108.
7. McGuire S. World cancer report 2014. Geneva, Switzerland: world Health organization, international Agency for research on cancer, WHO press. Adv Nutr 2015;7:418-9.
9. Levine DA. The Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
10. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, et al; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016;27:16-41.
11. Ruz-Caracuel I, Ramón-Patino JL, López-Janeiro Á, Yébenes L, Berjón A, et al. Pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma. Cancers 2019;11:e1845.
12. Marius Ilié M, Hofman P. Pros: Can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016;5:420-3.
13. García-Foncillas J, Tabernero J, Elena Élez E, Enrique Aranda E, Benavides M, et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer 2018;119:1464-70.
14. Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, et al. Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer. Prodige-14 Trial. Cells 2019;8:516.
15. Tuaeva NO, Falzone L, Porozov YB, Nosyrev AE, Trukhan VM, et al. Translational application of circulating DNA in oncology: review of the last decades achievements. Cells 2019;8:1251.
16. Mayo-de-Las-Casas C, Velasco A, Sanchez D, Martínez-Bueno A, Garzón-Ibáñez M, et al. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: a proof-of-concept study cancer. Int J Cancer 2020;147:277-84.
17. Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, et al. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer 2016;16:127.
18. Liu Q, Liao Q, Zhao Y. Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. Medical Hypotheses 2016;87:34-9.
19. Kloten V, Lampignano R, Krahn T, Schlange T. Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCL. Cells 2019;8:e809.
20. Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, et al. Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv 2018;36:1063-78.
21. Bankó P, Lee SY, Nagygyörgy V, Zrínyi M, Chae CH, et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol 2019;12:48.
22. Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, et al. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer 2014;13:223.
23. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, et al. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol 2016;10:e408-e417.
24. Muinelo-Romay L, Casas-Arozamena C, Abal M. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. Int J Mol Sci 2018;19:2311.
25. Pixberg CF, Schulz WA, Stoecklein NH, Neves RPL. Characterization of DNA methylation in circulating tumor cells. Genes 2015;6:1053-75.
26. Zhang Y, Qu X, Qu PP. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma. J BUON 2016;21:1491-5.
27. Kolbl AC, Wellens R, Koch J, Rack B, Hutter S, et al. Endometrial adenocarcinoma: analysis of circulating tumour cells by RT-qPCR. Anticancer Res 2016;36:3205-10.
28. Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, et al. Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. PLoSOne 2013;8:e58557.
29. Kiss I, Kolostova K, Matkowski R, Jędryka M, Czekański A, et al. Correlation between disease stage and the presence of viable circulating tumorcells in endometrial cancer. Anticancer Res 2018;38:2983-7.
30. Bogani G, Liu MC, Dowdy SC, Cliby WA, Kerr SE, et al. Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer Res 2015;35:683-8.
31. Walter CB, Taran FA, Wallwiener M, Rothmund R, Kraemer B, et al. Prevalence and prognostic value of disseminated tumor cells in primary endometrial, cervical and vulvar cancer patients. Future Oncol 2014;10:41-8.
32. Obermayr E, Sanchez-Cabo F, Tea MKM, Singer CF, Krainer M, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010;10:666.
33. Zou J, Wang E. eTumorType, an algorithm of discriminating cancer types for circulating tumor cells or cell-free DNAs in blood. Gen Prot Bioinformatics 2017;15:130-40.
34. Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res 2015;7:1203-13.
35. Lim SB, Lee WD, Vasudevan J, Lim WT, Lim CT. Liquid biopsy: one cell at a time. NPJ Precis Oncol 2019;3:23.
36. Snyder A, Morrissey MP, Hellmann MD. Use of circulating tumor DNA for cancer immunotherapy. Clin Cancer Res 2019;25:6909-15.
37. Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Camacho SC, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One 2015;10:e0145754.
38. Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, et al. Influence of pre-analytical phase on circulating cell free DNA (ccfDNA): the SPIDIA-DNAplas external quality assessment experience. Clin Chem Lab Med 2015;53:1935-42.
39. Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, et al. Detection of TP53/PIK3CA mutations in cell-free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer 2016;16:418-23.
40. Zeng C, Stroup EK, Zhang Z, Chiu BCH, Zhang W. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. Cancer Commun 2019;39:12.
41. Kerachian MA, Poudineh A, Thiery JP. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. Crit Rev Oncol Hematol 2019;144:102827.
42. Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res 2018;8:1947-56.
43. Vidal J, Taus A, Montagut C. Dynamic treatment stratification using ctDNA. Recent Results Cancer Res 2020;215:263-73.
44. Zhu Y, Yang T, Wu Q, Yang X, Hao J, et al. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: a meta-analysis. Cancer Med 2020;9:5699-707.
45. Koessler T, Paradiso V, Piscuoglio S, Nienhold R, Ho L, et al. Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms. Lab Invest 2020; doi: 10.1038/s41374-020-0459-7.
46. Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, et al. Clinical utility of combined circulating tumor cell and circulating tumor DNA assays for diagnosis of primary lung cancer. Anticancer Res 2020;40:3435-44.
47. Kerachian MA, Azghandi M, Javadmanesh A, Ghaffarzadegan K, Mozaffari-Jovin S. Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy. Cell Oncol (Dordr) 2020; doi: 10.1007/s13402-020-00536-2.
48. Pittella-Silva F, Chin YM, Chan HT, Nagayama S, Miyauchi E, et al. Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin Chem 2020;66:946-57.
49. Sato Y, Matoba R, Kato K. Recent advances in liquid biopsy in precision oncology research. Biol Pharm Bull 2019;42:337-42.
50. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer 2010;127:612-21.
51. Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol 2019;32:405-14.
52. Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, et al. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using cancer personalized profiling by deep sequencing. Sci Rep 2019;9:10426.
53. Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J ExpClin Cancer Res 2018;37:16.
54. Nakabayashi M, Kawashima A, Yasuhara R, Hayakawa Y, Miyamoto S, et al. Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour associated copy number alteration. Sci Rep 2018;8:11205.
55. Tanaka H, Tsuda H, Nishimura S, Nomura H, Kataoka F, et al. Role of circulating free alu DNA in endometrial cancer. Int J Gynecol Cancer 2012;22:82-6.
56. Cicchillitti L, Corrado G, De Angeli M, Mancini E, Baiocco E, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget 2017;8:115230-43.
57. An Q, Hu Y, Li Q, Chen X, Huang J, et al. The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients. PrecisClinMed 2019;2:131-9.
58. Pasha HA, Rezk NA, Riad MA. Circulating cell free nuclear DNA, mitochondrial DNA and global DNA methylation: potential noninvasive biomarkers for breast cancer diagnosis. Cancer Invest 2019;37:432-9.
59. Meng X, Schwarzenbach H, Yang Y, Müller V, Li N, et al. Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer. TranslOncol 2019;12:1213-20.
60. Afrifa J, Zhao T, Yu J. Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate. Mitochondrion 2019;47:238-43.
61. Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, et al. Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Res 2019;79:220-30.
62. Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, et al. Tumor-specific mitochondrial DNA variants are rarely detected in cell-freeDNA. Neoplasia 2018;20:687-96.
63. Tan ZQ, Liu FX, Tang HL, Su Q. Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer. Zhonghua Fu Chan Ke Za Zhi 2010;45:772-4.
64. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013;1:12.
65. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012;12:369.
66. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013;132:1633-45.
67. Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. GynecolOncol 2014;132:715-21.
68. Wang WT, Zhao YN, Yan JX, Weng MY, Wang Y, et al. Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery. J Hematol Oncol 2014;7:6.
69. Yu J, Wang Y, Dong R, Huang X, Ding S, et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol 2012;38:671-4.
70. Zhao S, Yao D, Chen J, Ding N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers 2013;17:631-6.
71. Chen J, Yao D, Li Y, Chen H, He C, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 2013;32:557-67.
72. Zhao YN, Chen G, Hong SJ. Circulating MicroRNAs in gynecological malignancies: from detection to prediction. Exp Hematol Oncol 2014;3:14.
73. Wang L, Chen YJ, Xu K, Xu H, Shen XZ, et al. Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma. PLoSOne 2014;9:e110767.
74. La Ferlita A, Battaglia R, Andronico F, Caruso S, Cianci A, et al. Non-coding RNAs in endometrial physiopathology. Int J Mol Sci 2018;19:2120.
75. Gao Y, Dai M, Liu H, He W, Lin S, et al. Diagnostic value of circulating miR-21: an update meta-analysis in various cancers and validation in endometrial cancer. Oncotarget 2016;7:68894-908.
76. Benati M, Montagnana M, Danese E, Paviati E, Giudici S, et al. Evaluation of mir-203 expression levels and DNA promoter methylation status in serum of patients with endometrial cancer. Clin Lab 2017;63:1675-81.
77. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 2004;24:1529-35.
78. Qu W, Gao Q, Chen H, Tang Z, Zhu X, et al. HE4-test of urine and body fluids for diagnosis of gynecologic cancer. Expert Rev Mol Diagn 2017;17:239-44.
79. Liang J, Yin G, Chen M, Wu A. Detection of hTERT mRNA in peripheral blood and its implication for diagnosis of early stage postoperative endometrial cancer micrometastasis. Panminerva Med 2016;58:206-10.
80. Nazarenko I. Extracellular vesicles: recent developments in technology and perspectives for cancer liquid biopsy. Recent Results Cancer Res 2020;215:319-44.
81. Mariscal J, Fernandez-Puente P, Calamia V, Abalo A, Santacana M, et al. Proteomic characterization of epithelial-like extracellular vesicles in advanced endometrial cancer. J Proteome Res 2019;18:1043-53.
82. Fitts CA, Ji N, Li Y, Tan C. Exploiting exosomes in cancer liquid biopsies and drug delivery. Adv Healthcare Mater 2019;8:1801268.
83. Lim W, Kim HS. Exosomes as therapeutic vehicles for cancer. Tissue Eng Regen Med 2019;16:213-23.
84. Xu H, Gong Z, Shen Y, Fang Y, Zhong S. CircularRNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics 2018;10:187-97.
86. Zavesky L, Jandakova E, Turyna R, Duskova D, Langmeierova L, et al. Cell-free urinary microRNAs expression in small-scale experiments. Methods Mol Biol 2017;1580:99-106.
87. Larsen LK, Lind GE, Guldberg P, Dahl C. DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies. Int J Mol Sci 2019;20:2657.
88. Ye F, Tang QL, Ma F, Cai L, Chen M, et al. Analysis of the circular RNA transcriptome in the grade 3 endometrial cancer. Cancer Manag Res 2019;11:6215-27.
89. Binesh F, Akhavan A, Behniafard N, Zabihi S, Hosseinizadeh E. Prognostic value of peritoneal washing cytology in gynecologic malignancies: a controversial issue. Asian Pac J Cancer Prev 2014;15:9405-10.
90. Lv S, Wang R, Wang Q, Han L, Tuo X, et al. A novel solution configuration on liquid-based endometrial cytology. PLoS One 2018;13:e0190851.
91. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
92. Zhang H, Wen J, Xu PL, Chen R, Yang X, et al. Role of liquid-based cytology and cell block in the diagnosis of endometrial lesions. Chin Med J (Engl) 2016;129:1459-63.
93. Norimatsu Y, Kouda H, Kobayashi TK, Shimizu K, Yanoh K, et al. Utility of liquid-based cytology in endometrial pathology: diagnosis of endometrial carcinoma. Cytopathology 2009;20:395-402.
94. Buccoliero AM, Gheri CF, Castiglione F, Garbini F, Barbetti A, et al. Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women. Cytopathology 2007;18:241-9.
95. Yap J, Salamonsen LA, Jobling T, Nicholls PK, Dimitriadis E. Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma. ReprodBiolEndocrinol 2010;8:63.
96. Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, et al. Lavage of the uterine cavity for molecular detection of Mullerian duct carcinomas: a proof-of-concept study. J Clin Oncol 2015;33:4293-301.
97. Martignetti JA, Pandya D, Nagarsheth N, Chen Y, Camacho O, et al. Case report: molecular detection of endometrial precancer using a targeted gynecologic cancer liquid biopsy. Cold Spring HarbMol Case Stud 2018;4:a003269.
98. Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLoS Med 2016;13:e1002206.
99. Roman-Canal B, Moiola CP, Gatius S, Bonnin S, Ruiz-Miró M, et al. EV-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer. Cancers 2019;11:839.
100. Galamb O, Barták BK, Kalmár A, Nagy ZB, Szigeti KA, et al. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol 2019;25:5026-48.
101. Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers 2019;11:1170.
